Biosimilars Conference 2010

Drawing on the strength of SMi's successful Generics, Supergenerics and Patent Strategies conference series, we are proud to present our inaugural Biosimilars & Biobetters: Aligning Business & Science for Success.
According to a recent report published by Biophoenix, in 2009 the biosimilar-susceptible segment of the biologic market was worth US$63 billion and by 2013 biosimilars could generate a total market of $5.6 billion. The key driver to biosimilar development is the expiry of patents across the older leading biologics and with many of these products beginning to come off patent between 2015 and 2016 this industry is set to grow at a significant pace.
Biosimilars have attracted a great deal of interest recently and are seen by some as the new generic frontier. It is widely thought that lower levels of competition will lead to higher margins in an industry notorious for its generally low margins on commodity generics. Payer pressure is expected to drive uptake, particularly in the German, UK and US markets.